Financial Services · Financial - Data & Stock Exchanges · Synthos Deep Dive · 2026-07-03
| Verdict | Buy — Core — systematic Synthos tier |
| Price (2026-07-03) | $248.99 · market cap ~$26.1B |
| Synthos scores (0–10) | Downside Risk 3 · Growth Quality 7 · Exponential Potential 4 |
| Synthos fair value (base case) | ~$287 → +15% · full range $192 (bear) – $384 (bull) |
| Street consensus | $302 (high $335 / low $263; 15 Buy · 12 Hold · 4 Sell) — context, not our anchor |
| Valuation | 21× trailing EPS · 18× FY26E · 17× FY27E · 13× FY30E · EV/EBITDA 13.4× · P/S 5.4× |
| Exponential Potential | 4/10 · Moderate — near-term growth is accelerating (Q1'26 net rev +29%, guidance raised), but the through-cycle EPS CAGR is ~12% and the TAM is modest |
| Technicals | Downtrend / oversold — $249, −32% off the 52-wk high, below 50/200-DMA, RSI 26, +7% 12-mo (SPY +21%) |
| Conviction | Low — only 1 net-bullish KB voice (+55). This is a fundamentals-and-quant call, not a conviction-panel call |
| Position sizing | Tactical / value-recovery, ~2–3% satellite weight (not a core anchor) |
| Next catalyst | 2026-07-31 Q2'26 earnings (Street EPS $3.30) |
| Single biggest risk | A structural shift to 24/7 crypto-style perpetual futures and tokenized markets that erodes CBOE's listed-derivatives franchise |
One-line thesis. CBOE is a genuinely wide-moat, net-cash, ~25%-ROE derivatives-exchange monopolist (proprietary SPX and VIX options) that just posted a record quarter (net revenue +29%, EPS +54%) and raised guidance — yet the stock is down 32% from its high on fears that perpetual futures and tokenization will displace listed products. If those fears are overdone, today's 21× P/E on an accelerating compounder is a tactical buy; if they are not, the discount is deserved.
Cboe (say "see-bo") runs financial exchanges — the marketplaces where traders buy and sell options and futures. Its crown jewel is that it owns the most important index options in the world: contracts on the S&P 500 (SPX) and the market's "fear gauge" (VIX). Nobody else is allowed to list those, so Cboe collects a fee on enormous, growing trading volume with very little competition. It's a toll booth on Wall Street's risk-management traffic.
The business is doing great: last quarter revenue grew about 29% and profit per share jumped 54%, and management told investors 2026 will be even better than they'd promised. The company has more cash than debt and doesn't swing around much day-to-day.
So why is the stock down about a third from its peak? Investors got scared that new "always-on" crypto-style products (called perpetual futures) and tokenized markets could pull trading away from Cboe's old-fashioned listed contracts. That fear is the whole debate.
Our verdict is Buy — Tactical: buy it as a bounce-back value idea, in a smaller-than-core size, because the price already looks cheap for the quality — but keep the size modest because the disruption worry is real, not imaginary.
Here's what the three scores mean in everyday terms:
The one big worry: if trading permanently migrates to 24/7 perpetual-futures and tokenized venues, Cboe's protected franchise erodes and the cheap price turns out to be a trap.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 36.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = CBOE · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
“Exchange-stock crash on fears perps displace listed futures is overdone; the selloff is an overreaction.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Cboe Global Markets (BATS: CBOE) is a global exchange operator founded in Chicago in 1973, best known as the home of listed options — and specifically the proprietary, exclusively-licensed SPX (S&P 500) and VIX index-options franchise, which is the profit engine and the source of the moat. The company reports five segments: Options (the crown jewel), North American Equities (cash equities/ETPs in the US and Canada), Europe and Asia Pacific, Futures, and Global FX. Alongside trading it runs a fast-growing recurring-revenue data business, Cboe Data Vantage (market data, analytics, and access/capacity fees). Fiscal year ends December 31; CEO is Craig Donohue (in seat ~1 year, driving a strategic realignment).
A crucial reporting note (read before the financials). Exchanges are reported two ways. FMP's income statement shows gross revenue (FY25 $4,714M), which includes large pass-through items — liquidity payments, routing/clearing, Section 31 fees — that CBOE collects and remits. What management and analysts actually track is net revenue (revenue less cost of revenue): Q1'26 net revenue was $728.9M, up 29% per the earnings release, and the full-year analyst estimates (~$2.4–3.3B) are on this net basis. Throughout this note, growth and margin commentary use the net-revenue frame; where a number is gross, it is labeled.
Revenue mix — net revenue by segment (Q1'26, from the earnings release):
By revenue caption (FY25 gross, from filings): Transaction & clearing fees $3,597.6M · Access & capacity fees $408.7M · Market data fees $326.6M · Regulatory fees $285.4M · Other $95.9M. The Access/capacity + Market data lines (~$735M gross) are the sticky, recurring Data Vantage revenue that management is investing behind. (FMP's geographic segmentation is incomplete for FY25 — it lists only North American Equities $1,672M and Europe/APAC $379M — so the segment table above from the earnings release is the reliable cut.)
Honest breadth statement: the Synthos KB has exactly one claim on CBOE. This is not a conviction-panel name like our flagship healthcare ideas; the verdict here is fundamentals- and quant-driven, with the single expert voice used only as corroboration.
compound_and_friends-QzbZSLClQag:90df227007, bullish, conviction 55, skill 1.0): the "exchange-stock crash on fears that perps displace listed futures is overdone; the selloff is an overreaction." That claim maps precisely onto what the tape shows — CBOE down 32% from its high while fundamentals accelerated — which is the crux of the Buy — Tactical case.That is the entire expert record. There is no bearish KB voice on file and no high-breadth panel, so we do not manufacture conviction we don't have: the score and the verdict below are built from the financials, the valuation, and the disruption debate on their own merits.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 3 · Fairly Low | Net-cash balance sheet (net debt −$0.53B, −0.30× EBITDA), 0.40 beta, non-cyclical fee model, and a reasonable 21× P/E / 13.4× EV/EBITDA cushion the downside. Offsetting: a −32% drawdown in an active downtrend and a genuine secular-disruption flag keep it off a 1–2. |
| Growth Quality | 7 · High | Q1'26 net revenue +29% and diluted EPS +54%; guidance raised; ~25% ROE, ~52% net-revenue net margin, and a regulatory/proprietary-product moat. Held below 8 by a ~12% through-cycle EPS CAGR and volume-linked cyclicality. |
| Exponential Potential | 4 · Moderate | Near-term growth is genuinely accelerating (guidance raise, record volumes), but the structural rate is mid-single to low-double digit, the TAM is modest, and the disruption story is a threat — not an accelerant. A small accelerating name would score higher; a $26B fee compounder does not. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Perps/tokenization fear proves overdone; SPX/VIX volumes and Data Vantage keep compounding; realignment lifts margins. FY27E EPS beats to ~$16 (top of range) and the multiple re-rates back toward its historical ~24×. | ~$384 (+54%) |
| Base (our anchor) | Guidance broadly holds; FY27E EPS ~$14.4 (consensus); a durable ~25%-ROE monopolist earns a ~20× multiple (below its own history, crediting the disruption overhang). | ~$287 (+15%) |
| Bear | Perpetual futures and tokenized venues durably siphon derivatives volume; growth fades to low-single-digit; FY27E EPS ~$12 and the multiple de-rates to ~16×. | ~$192 (−23%) |
Synthos fair value = the base case, ~$287 (+15%), with the full $192–$384 span as the honest range. Our base sits just below the Street's $302 consensus (we apply a disruption haircut to the multiple) while our bull roughly matches the Street's $335 high. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). CBOE is a high-quality compounder with a genuine near-term acceleration, but structurally capped:
Exponential Potential: Moderate (4/10). Own CBOE for a ~25% ROE, a protected franchise, and a credible near-term earnings acceleration at a fair price — not for a fast multibagger.
CBOE is not expensive on its own history or on forward earnings — the debate is entirely about whether the earnings are durable:
Read: a quality-franchise-at-a-fair-price buy, not a deep-value bargain and not an expensive momentum name.
CBOE's moat is one of the widest in financial services and rests on three pillars: (1) proprietary, exclusively-licensed products — SPX and VIX index options cannot be listed elsewhere, so CBOE captures the economics of the single most important equity-index-volatility complex; (2) network liquidity — options liquidity begets liquidity, entrenching incumbents; and (3) a growing recurring data/access franchise (Data Vantage) that is stickier and less volume-cyclical than transaction fees. Returns on capital (~25% ROE) and ~70% operating margins are the financial signature of that moat.
The threat — and the reason the stock is down — is structural: perpetual futures (24/7, crypto-native contracts) and tokenization could route derivatives and equities volume to always-on, off-exchange venues, eroding the protected franchise over time. Management is not passive — it is explicitly investing in tokenization initiatives, event markets, and expanded clearing (see §9) — but this is the open question the multiple is pricing.
Peer set (market cap, from FMP). FMP's "peers" list is a loose financials basket, not a clean exchange comp: Tradeweb (TW) $21.9B and Futu (FUTU) $13.3B are the closest market-structure names; the rest — Cincinnati Financial (CINF) $29.7B, First Citizens (FCNCA) $24.1B, Huntington (HBAN) $36.2B, LPL Financial (LPLA) $23.6B, Markel (MKL) $24.8B, Shinhan (SHG) $31.6B, U.S. Bancorp (USB) $95.8B — are banks/insurers. CBOE's truest comps (ICE, CME, Nasdaq, LSEG) are not in this list; on the standard exchange-peer frame CBOE typically screens with the highest margins and a mid-pack multiple.
- Raised 2026 total organic net-revenue growth target to "low double-digit to mid-teens" from "mid single-digit."
- Raised Data Vantage organic net-revenue growth target to "low double-digit" from "mid-to-high single-digit."
- Lowered 2026 adjusted operating-expense guidance to $838–$853M from $864–$879M (via a strategic realignment cutting workforce ~20%, and selling Cboe Canada and Cboe Australia).
- CEO Donohue framed a portfolio "realignment" to concentrate on core earnings drivers and invest in event markets, tokenization, and expanded US/Europe clearing.
- Half-weight caveat: this is management's own framing after a record quarter — genuinely positive, but it is the bull's evidence and should be read alongside the technicals in §7, which disagree.
Thesis tripwires (what would change the call): two consecutive quarters of Options volume deceleration; concrete evidence of durable volume migration to perps/tokenized venues; net-revenue growth slipping below the raised guidance range; or the multiple staying depressed while estimates get cut (a value trap confirming).
compound_and_friends-QzbZSLClQag:90df227007) — but "overdone" is a judgment, not a fact, and the tape currently disagrees.Buy — Tactical. CBOE is a wide-moat, net-cash, ~25%-ROE derivatives monopolist that just posted a record quarter (net revenue +29%, EPS +54%) and raised guidance, trading at ~18× forward and −32% off its high because the market fears perpetual futures and tokenization will erode the franchise. If that fear is overdone — as the one traceable KB voice argues and the accelerating fundamentals suggest — today's price is an attractive entry into quality. But the fear is not baseless, the chart is in a confirmed downtrend, and expert breadth is a single voice, so this is a Tactical, satellite-sized recovery idea, not a Core anchor.
claim_id (cited inline). This is explicitly a fundamentals-and-quant verdict; conviction is rated Low by design because expert breadth is a single voice. Fabricated conviction is structurally impossible (claim-ID reconciliation).